Pfiz­er in­fus­es $200M in­to CStone, scor­ing a sec­ond PD-L1 and out­lin­ing a sprawl­ing Chi­na pact

5 years ago
Deals
China

Brent Saun­ders rides $400M wave to the top of the SPAC boom

5 years ago
Financing

Covid-19 roundup: No­var­tis' Vas Narasimhan sees drugs as 'bridge' to vac­cines; Mod­er­na spot­lights el­der­ly re­spons­es ...

5 years ago
Coronavirus

Re­gen­eron of­fers a pos­i­tive look at the first cut of its Covid-19 an­ti­body cock­tail — but just how well does it ...

5 years ago
R&D
Coronavirus

Black Di­a­mond brings in ex-GSK CEO Bob In­gram to chart new path in pre­ci­sion on­col­o­gy

5 years ago
People

News brief­ing: PhI­II Alzheimer's play draws an­oth­er $33M+; Ar­ran­ta un­veils $100M+ mi­cro­bio­me man­u­fac­tur­ing site

5 years ago
News Briefing

Eye­ing their first ap­proval, Bridge­Bio sends their first drug to the FDA and lands a speedy re­view

5 years ago
R&D
FDA+

My­ovant shows dis­ap­point­ing prostate can­cer da­ta on the way to the FDA, stock sinks

5 years ago
R&D

Belén Gar­i­jo ris­es to the top at Mer­ck KGaA amid ex­ec board makeover

5 years ago
People

Two years af­ter Alex Den­ner ac­tivist at­tack, Iron­wood plots mass lay­offs as last clin­i­cal pro­gram goes up in smoke

5 years ago
R&D

Armed with a PhI can­cer drug from Bay­er, an Ac­er­ta founder breaks cov­er and writes him­self a $60M blank check deal

5 years ago
Financing
Deals

MPM joins the his­toric SPAC boom as its blank check com­pa­ny files for an IPO

5 years ago
Financing

Covid-19 roundup: JA­MA study says peo­ple 65+ like­ly ex­clud­ed from tri­als; Trump plans roll­out of 150 mil­lion rapid ...

5 years ago
Coronavirus

Rac­ing ahead of Mer­ck and In­novent, Jun­shi de­clares PhI­II suc­cess on can­cer that won them 'break­through' sta­tus

5 years ago
R&D

Hooked by the sci­ence, Arie Bellde­grun joins a group of in­flu­en­tials who be­lieve Dew­point may have the key to the ...

5 years ago
Financing
R&D

Slammed by FDA re­jec­tion, Aque­s­tive vows to re­file by end of year

5 years ago
FDA+

One year af­ter Fetro­ja ap­proval, Sh­iono­gi ex­pands la­bel to in­clude dif­fi­cult-to-treat pneu­mo­nia

5 years ago
R&D
FDA+

Covid-19 roundup: Re­searchers urge Pfiz­er to adopt high safe­ty stan­dard, hold vac­cine EUA un­til late No­vem­ber

5 years ago
Coronavirus

Ali­gos Ther­a­peu­tics, de­vel­op­ing sev­er­al dif­fer­ent hep B and NASH treat­ments, files for $100M IPO raise

5 years ago
Financing

News brief­ing: Bio­gen gets a quick date with an FDA pan­el for con­tro­ver­sial ad­u­canum­ab; Abeona CEO, board mem­bers ...

5 years ago
News Briefing

In­ven­tis­Bio reels in $147M to push gout and breast can­cer drugs along

5 years ago
Financing
R&D

Look­ing to con­quer new ter­ri­to­ries, Or­biMed joins a $60M bet on a Bio­haven spin­out in Shang­hai

5 years ago
Financing

Covid-fat­tened shares crash as FDA puts a late-stage coro­n­avirus vac­cine tri­al on hold

5 years ago
FDA+

Soft­Bank, Morn­ing­side help put US-Chi­na AI play­er on the map with $318M bet

5 years ago
Financing
China
First page Previous page 796797798799800801802 Next page Last page
A service from the Financial Times